Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
Line 12: | Line 12: | ||
*[[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21, 2017]] | *[[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21, 2017]] | ||
*[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | *[[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17, 2017]] | ||
− | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' |
Revision as of 16:42, 21 February 2018
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive